Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients

Kotowicz, Beata; Fuksiewicz, Małgorzata; Jońska-Gmyrek, Joanna; Berezowska, Alicja; Radziszewski, Jakub; Bidziński, Mariusz; Kowalska, M

doi:10.1371/journal.pone.0184576

Cited by 23 publications

(30 citation statements)

References 25 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This discrepancy might be related to different concentrations obtained in healthy controls group. In oppose to our findings were results obtained by Kotowicz et al [27], where concentrations of VEGF-A and VEGFR-2 were not statistically significant, but their work concerned different type of tumor (endometrial cancer).…”

Section: Discussioncontrasting

confidence: 99%

“…Statistically significant plasma over expression and high gene expression of VEGF-A, VEGF-C, VEGF-D and VEGFR-2 have been detected in patients suffering from many types of tumors, also breast cancer [6, 9, 23–27]. We have demonstrated statistically significantly higher plasma concentrations of almost all tested parameters when compared to control groups.…”

Section: Discussionmentioning

confidence: 53%

See 1 more Smart Citation

Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor - VEGFR-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of Breast Cancer

Zajkowska

Lubowicka

Fiedorowicz

et al. 2018

Pathol. Oncol. Res.

View full text Add to dashboard Cite

VEGF family members are important factors in promoting angio- and lymphangiogenesis. The aim of this study was to investigate concentrations, diagnostic utility and power of VEGF-A, VEGF-C, VEGF-D and VEGFR-2 in comparison to CA15–3 in breast cancer (BC) patients. The study included 120 BC patients and 60 control patients (28 with benign breast tumors and 32 healthy women). Plasma levels of tested parameters were determined by ELISA, CA15–3 by CMIA. Concentrations of all parameters showed statistical significance when compared BC patients to controls. VEGF-D showed the highest SE (82.50%) in total BC group. Highest SP and PPV in total BC group showed VEGF-A(76.67%;84.78%,respectively), but lower than CA15–3. Highest NPV showed VEGF-C(52.33%), but it was lower than CA15–3. VEGF-C was also the best parameter which had statistically significant AUC in total cancer group (0.7672), but also stages I(0.7684) and II(0.7772). In the total group of BC almost all tested parameters showed statistically significant AUC, but a maximum range was obtained for the combination of VEGF-C + CA15–3(0.8476). The combined analysis of tested parameters and CA15–3 resulted in increase in SE and AUC values, which provides hope for developing a new panel of biomarkers that may be used in the diagnosis of BC in the future.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionmentioning

confidence: 53%

Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor - VEGFR-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of Breast Cancer

Zajkowska

Lubowicka

Fiedorowicz

et al. 2018

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

“…Due to the sustained action of VEGF, a large number of new blood vessels can be produced in the progression of endometrial cancer. The new blood vessels not only provide the tumor tissue with the nutrients necessary for growth, but they also remove metabolic products [50,51]. As a major regulator of neovascularization in endometrial cancer, HIF-1 directly regulates the expression of VEGF at the gene level.…”

Section: Signaling Pathways In Endometrial Carcinogenesismentioning

confidence: 99%

Epithelial to Mesenchymal Transition and Cell Biology of Molecular Regulation in Endometrial Carcinogenesis

Chiu

Yiang

et al. 2019

JCM

View full text Add to dashboard Cite

Endometrial carcinogenesis is involved in several signaling pathways and it comprises multiple steps. The four major signaling pathways—PI3K/AKT, Ras/Raf/MEK/ERK, WNT/β-catenin, and vascular endothelial growth factor (VEGF)—are involved in tumor cell metabolism, growth, proliferation, survival, and angiogenesis. The genetic mutation and germline mitochondrial DNA mutations also impair cell proliferation, anti-apoptosis signaling, and epithelial–mesenchymal transition by several transcription factors, leading to endometrial carcinogenesis and distant metastasis. The PI3K/AKT pathway activates the ransforming growth factor beta (TGF-β)-mediated endothelial-to-mesenchymal transition (EMT) and it interacts with downstream signals to upregulate EMT-associated factors. Estrogen and progesterone signaling in EMT also play key roles in the prognosis of endometrial carcinogenesis. In this review article, we summarize the current clinical and basic research efforts regarding the detailed molecular regulation in endometrial carcinogenesis, especially in EMT, to provide novel targets for further anti-carcinogenesis treatment.

show abstract

“…Interesting observations are also provided by studies on a group of 118 patients with endometrial cancer carried out by Kotowicz et al , in which they analyzed the expression profile of VEGF-A, VEGFR-1, VEGFR-2 and IL-8. They emphasize the clinical value of IL-8 and VEGFR-2 as potential prognostic factors and that increased VEGF-A activity may be useful in pre-operative assessment of para-aortic lymph node status [ 33 ]. Mathur et al observed elevated serum level of VEGF-B in early, advanced and persistent cervical cancer, as well as in ovarian and endometrial cancer.…”

Section: Discussionmentioning

confidence: 99%

Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer

Dziobek

Opławski²,

Grabarek

et al. 2019

CPB

View full text Add to dashboard Cite

Background: VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 are important proteins involved in the induction and development of a new blood vessel network through which the tumor is properly nourished and oxygenated. Objective: The aim of the study was to evaluate changes in VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 expression in endometrial cancer depending on its grade and to determine the VEGFR-1 to VEGFR-2 concentration ratio. Methods: The study group consisted of 45 patients diagnosed with endometrial cancer (G1, 17; G2, 15; G3, 13). The control group included 15 patients. VEGF-A, VEGF-B, VEGF-R1, VEGFR-2 expression was assessed using the immunohistochemical method. Statistical analysis was carried out using the Statistica 12 PL program (StatSoft, Cracow, Poland). It included the one-way ANOVA and Tukey's post-hoc test (p<0.05). Results: Statistically significant differences in the level of VEGF-A, VEGF-B, VEGF-R1, VEGFR-2 were observed between the majority of analyzed groups (except for VEGF-B; G3 vs. G1, p=0.997700). The expression pattern of VEGF-A, VEGF-R1, VEGFR-2 was as follows: G3>G2>G1>C; VEGF-B: G2> G3> G1>C. A lower concentration of VEGFR-1 than VEGFR-2 was found regardless of the cancer grade. Conclusion: VEGF-A, VEGF-B, VEGF-R1, VEGFR-2 are key proteins involved in tumor angiogenesis. The analysis of the entire panel of proteins participating in a given process is an important element of modern diagnostics. The concentration ratio of VEGFR-1 to VEGFR-2 appears to be a determining factor in the patients' survival prognosis.

show abstract

Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients

Cited by 23 publications

References 25 publications

Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor - VEGFR-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of Breast Cancer

Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor - VEGFR-2 and Applicability of these Parameters as Tumor Markers in the Diagnostics of Breast Cancer

Epithelial to Mesenchymal Transition and Cell Biology of Molecular Regulation in Endometrial Carcinogenesis

Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer

Contact Info

Product

Resources

About